These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19179977)

  • 21. Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients.
    Mehdipour P; Pirouzpanah S; Sarafnejad A; Atri M; Shahrestani ST; Haidari M
    Cell Biol Int; 2009 Oct; 33(10):1050-6. PubMed ID: 19555767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer.
    Kühling H; Alm P; Olsson H; Fernö M; Baldetorp B; Parwaresch R; Rudolph P
    J Pathol; 2003 Apr; 199(4):424-31. PubMed ID: 12635132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer.
    Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
    J Surg Oncol; 2003 Aug; 83(4):241-7. PubMed ID: 12884237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic relevance of basal cytokeratin expression in operable breast cancer.
    Potemski P; Kusinska R; Watala C; Pluciennik E; Bednarek AK; Kordek R
    Oncology; 2005; 69(6):478-85. PubMed ID: 16410686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer.
    Koliadi A; Nilsson C; Holmqvist M; Holmberg L; de La Torre M; Wärnberg F; Fjällskog ML
    Acta Oncol; 2010 Aug; 49(6):816-20. PubMed ID: 20307242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.
    Skalicky DA; Kench JG; Segara D; Coleman MJ; Sutherland RL; Henshall SM; Musgrove EA; Biankin AV
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1941-7. PubMed ID: 17035403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer.
    Kim HK; Park IA; Heo DS; Noh DY; Choe KJ; Bang YJ; Kim NK
    Eur J Surg Oncol; 2001 Aug; 27(5):464-71. PubMed ID: 11504517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer.
    Waltersson MA; Askmalm MS; Nordenskjöld B; Fornander T; Skoog L; Stål O
    Int J Oncol; 2009 Feb; 34(2):441-8. PubMed ID: 19148479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study.
    Farley J; Smith LM; Darcy KM; Sobel E; O'Connor D; Henderson B; Morrison LE; Birrer MJ;
    Cancer Res; 2003 Mar; 63(6):1235-41. PubMed ID: 12649182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer.
    Bani-Hani KE; Almasri NM; Khader YS; Sheyab FM; Karam HN
    Clin Cancer Res; 2005 Feb; 11(4):1447-53. PubMed ID: 15746045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ki-67 expression in operable breast cancer: a comparative study of immunostaining and a real-time RT-PCR assay.
    Potemski P; Pluciennik E; Bednarek AK; Kusinska R; Kubiak R; Jesionek-Kupnicka D; Watala C; Kordek R
    Pathol Res Pract; 2006; 202(7):491-5. PubMed ID: 16678980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors.
    Grabowski P; Schrader J; Wagner J; Hörsch D; Arnold R; Arnold CN; Georgieva I; Stein H; Zeitz M; Daniel PT; Sturm I
    Clin Cancer Res; 2008 Nov; 14(22):7378-84. PubMed ID: 19010853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression levels of cyclin G2, but not cyclin E, correlate with gastric cancer progression.
    Choi MG; Noh JH; An JY; Hong SK; Park SB; Baik YH; Kim KM; Sohn TS; Kim S
    J Surg Res; 2009 Dec; 157(2):168-74. PubMed ID: 19559447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
    Aaltonen K; Amini RM; Landberg G; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H; Blomqvist C
    Breast Cancer Res Treat; 2009 Jan; 113(1):75-82. PubMed ID: 18240019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients.
    Farmen RK; Nordgård O; Gilje B; Shammas FV; Kvaløy JT; Oltedal S; Heikkilä R
    Breast Cancer Res Treat; 2008 Mar; 108(2):251-8. PubMed ID: 17492378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of 70-gene prognosis signature in node-negative breast cancer.
    Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
    Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
    Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
    Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.